Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why

  • Mizuho updated the price target for Cerevel Therapeutics Holdings Inc CERE from $27 to $32 keeping the Neutral rating.
  • The updated model reflects additional de-risking of emraclidine (a novel M4 PAM for schizophrenia) following the announcement of positive Phase 3 data for KarXT, a similarly acting drug Karuna Therapeutics Inc's KRTX schizophrenia drug.
  • Related: Karuna Therapeutics Shares Surge After Encouraging Data From Schizophrenia Candidate.
  • After increasing the probability of success assumption to 70% (from 60%) for emraclidine, and making refinements to product revenue build, the peak US risk adjusted/unadjusted emraclidine sales forecast increases slightly to $3.4 billion/$2.4 billion from the prior $3.3 billion/$2 billion. 
  • Related: Cerevel's Acute Anxiety Candidate Shows Encouraging Action In Healthy Volunteers.
  • Mizuho analyst believes that based on the solid Phase 3 data results for KarXT, and the previously reported positive Phase 1b/2 data for emraclidine, the following clinical datasets should be positive and supportive.
  • Price Action: CERE shares are up 3.28% at $33.67 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!